Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 275.30M | 277.10M | 279.00M | 234.30M | 182.70M |
Gross Profit | 122.50M | 116.40M | 81.90M | 68.50M | 42.80M |
EBITDA | 77.70M | 30.00M | 80.60M | 74.20M | 57.30M |
Net Income | 12.40M | -30.70M | 16.80M | 11.50M | 200.00K |
Balance Sheet | |||||
Total Assets | 553.70M | 549.40M | 615.20M | 605.60M | 497.30M |
Cash, Cash Equivalents and Short-Term Investments | 8.00M | 22.70M | 30.20M | 32.90M | 26.40M |
Total Debt | 237.00M | 224.00M | 243.20M | 250.70M | 213.20M |
Total Liabilities | 319.90M | 317.30M | 342.00M | 340.40M | 278.70M |
Stockholders Equity | 233.80M | 232.10M | 273.20M | 265.20M | 218.60M |
Cash Flow | |||||
Free Cash Flow | 42.80M | 37.50M | 36.80M | 38.90M | 44.40M |
Operating Cash Flow | 58.50M | 47.80M | 47.80M | 47.70M | 51.70M |
Investing Cash Flow | -15.60M | -12.00M | -22.50M | -95.50M | -11.00M |
Financing Cash Flow | -60.80M | -43.30M | -28.00M | 54.30M | -30.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | 326.54M | 12.97 | 5.28% | 14.10% | -0.78% | 0.00% | |
70 Outperform | 1.81B | 16.90 | 24.71% | 3.11% | 14.34% | -16.43% | |
66 Neutral | 9.11B | 35.64 | 7.26% | 2.06% | -1.58% | -34.64% | |
64 Neutral | £368.33M | 39.21 | 4.01% | 2.23% | 6.90% | ― | |
59 Neutral | 294.04M | 18.00 | 38.37% | ― | -4.87% | 0.00% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Restore PLC reported a 15% increase in revenue to £160.1 million for the first half of 2025, driven largely by recent acquisitions. The company improved its adjusted operating margin to 17.7% and increased its adjusted profit before tax by 10% to £18.0 million. Despite a rise in net debt due to acquisitions, the company maintained strong cash generation and increased its interim dividend by 10%. Strategic highlights include a significant medical record scanning contract with Oxford University Hospitals and progress in its Information Management property consolidation program. The company remains confident in achieving its medium-term target of a 20% adjusted operating margin.
The most recent analyst rating on (GB:RST) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Restore stock, see the GB:RST Stock Forecast page.
Restore plc announced an upcoming Investor Presentation to discuss its half-year results for the period ending 30 June 2025. The event, hosted by CEO Charles Skinner and CFO Dan Baker, will be held online on 1 August, allowing stakeholders to engage directly with the company’s leadership and gain insights into its financial performance and strategic direction.
The most recent analyst rating on (GB:RST) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Restore stock, see the GB:RST Stock Forecast page.
Restore PLC, a UK-based company, has announced a change in its major holdings as Harwood Capital LLP has acquired additional voting rights, increasing its total to 12.071%. This acquisition reflects a slight increase from the previous 11.9898% and involves several entities including Oryx International Growth Fund Limited and Rockwood Strategic Plc. The change in holdings could potentially impact Restore PLC’s strategic decisions and influence its market positioning.
The most recent analyst rating on (GB:RST) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Restore stock, see the GB:RST Stock Forecast page.
Restore PLC, a UK-based company, has announced a change in its major holdings. Harwood Capital LLP has adjusted its voting rights in Restore PLC, reducing its stake from 12.014680% to 11.989800%. This change was officially notified on June 16, 2025, following the crossing of the threshold on June 13, 2025. The adjustment in holdings may impact Restore PLC’s shareholder dynamics and could influence its strategic decisions moving forward.
The most recent analyst rating on (GB:RST) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Restore stock, see the GB:RST Stock Forecast page.